InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results
May 06 2021 - 07:30AM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (NASDAQ:INM; TSX:IN), a clinical-stage company
developing pharmaceutical-based drug candidates and leading the way
in the clinical development of cannabinol (“CBN”), will report
financial results on Thursday, May 13, 2021 for the third quarter
of fiscal year 2021 ending March 31, 2021.
Conference Call & Webcast*:Thursday, May
13, 2021 at 8:00 AM Pacific Time, 11:00 AM Eastern TimeUS/CANADA
Participant Toll-Free Dial-In Number: +1 (855) 605-1745US/CANADA
Participant International Dial-In Number: +1 (914)
987-7959Conference ID: 3186833Webcast:
https://edge.media-server.com/mmc/p/ajuejmko (*Webcast replay
available for 90 days)
The Company’s full financial statements and related MD&A for
the third quarter ending March 31, 2021 will be available at
www.inmedpharma.com, www.sedar.com and at www.sec.gov on May 13,
2021.
About InMed: InMed Pharmaceuticals is a
clinical-stage company developing a pipeline of cannabinoid-based
pharmaceutical drug candidates, initially focused on the
therapeutic benefits of cannabinol (CBN), in diseases with high
unmet medical need. The Company is dedicated to delivering new
therapeutic alternatives to patients that may benefit from
cannabinoid-based pharmaceutical drugs. For more information,
visit www.inmedpharma.com.
Investor Contact: Edison GroupJoe Green/Laine
YonkerT: +1.646.653.7030/+1.646.653.7035E: jgreen@edisongroup.com
lyonker@edisongroup.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
information") within the meaning of applicable securities laws.
Forward-looking information is based on management's current
expectations and beliefs and is subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements.
Forward-looking information in this news release includes
statements about: delivering new therapeutic alternatives to
patients that may benefit from cannabinoid-based medicines;
developing a pipeline of cannabinoid-based medications, initially
focused on the therapeutic benefits of cannabinol; leading the way
in the clinical development of cannabinol; and reporting financial
results on May 13, 2021.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES
PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.